New combo attack on myeloma: antibody first, then CAR-T
NCT ID NCT07185477
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tests whether giving a bispecific antibody (QLS32015) before CAR-T cell therapy can improve outcomes for 20 adults with relapsed/refractory multiple myeloma. The study measures how many patients respond and tracks side effects. It is a single-arm, open-label design, so results will be compared to historical data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QLS32015 (a bispecific antibody targeting GPRC5D and CD3) and BCMA CAR-T cells
- What this could lead to
- If successful, this approach could improve treatment responses for patients with hard-to-treat multiple myeloma by using a two-step immune therapy.
- What could go wrong
- This is a very early, small trial (20 people) with no control group. The combination may cause serious side effects or not work better than existing options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for tough myeloma: early trial of BP2202 begins
- Can a Pre-Dose prevent a dangerous reaction in multiple myeloma treatment?
- New drug combo aims to tackle Hard-to-Treat myeloma
- New hope for myeloma patients: epunamin combo under study
- New combo therapy aims to tackle Hard-to-Treat myeloma
- New drug duo aims to tackle Hard-to-Treat myeloma